Results 281 to 290 of about 2,215,107 (353)
ABSTRACT Background Stent underexpansion significantly heightens the risk of major adverse cardiac events (MACE), and available treatment options for this condition remain limited. Intravascular Lithotripsy (IVL) technology disrupts superficial and deep calcium by using localized pulsative sonic pressure waves, emerges as a promising tool for ...
Marios Sagris+9 more
wiley +1 more source
ABSTRACT Transcatheter aortic valve implantation (TAVI) has changed the treatment of aortic stenosis. The Myval transcatheter heart valve (THV), a novel balloon‐expandable THV, has shown promising outcomes. Our aim is to compare the comparative safety and effectiveness of Myval THV against established THVs, such as Sapien and Evolut.
Anastasios Apostolos+8 more
wiley +1 more source
ABSTRACT Background Up to 50% of patients with ST‐segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) develop coronary microvascular dysfunction (CMD). Aims This study aims to assess whether a prothrombotic state of coronary blood, defined by thromboelastography (TEG), is associated with post ...
Roberto Scarsini+15 more
wiley +1 more source
CORONARY ARTERY DISSECTION: A COMPLICATION OF CANNULATION
Alfred Heilbrunn, Jack M. Zimmerman
openalex +1 more source
ABSTRACT Background Treating ostial left circumflex artery (LCx) lesions in percutaneous coronary intervention (PCI) for left main disease (LMD) remains a challenge. Despite recent recommendations for the use of drug‐coated balloon (DCB) in this lesion, there are concerns about crossover‐stenting from the left main trunk (LMT) to the left anterior ...
Takayuki Warisawa+10 more
wiley +1 more source
Effect of Aortic Insufficiency on Phasic Flow Patterns in the Coronary Artery
Robert B. Karp, Benson B. Roe
openalex +2 more sources
ABSTRACT Background The effects of phosphodiesterase 5 (PDE5) inhibitors on the incidence of long‐term outcomes in patients with cardiovascular disease are not well understood. Objective: We studied the association between PDE5 inhibitor therapy and the incidence of adverse cardiovascular major adverse cardiovascular events (MACE) in patients ...
Sumon Roy+5 more
wiley +1 more source
ABSTRACT Valve‐in‐valve (ViV) Transcatheter aortic valve replacement (TAVR) has emerged as a valid treatment option in symptomatic patients with failed aortic bioprosthetic valves, most especially in those with intermediate, high or prohibitive risk of surgery. Due to the unique design of stentless bioprosthetic valves with absence of visible posts and
Adeogo Akinwale Olusan+3 more
wiley +1 more source